Benefits and limitations of continuous glucose monitoring in type 1 diabetes

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81–S90.
   PubMedGoogle Scholar
• American Diabetes Association Standards of Medical Care in Diabetes. Diabetes care: the journal of clinical and applied research and education. Diabetes Care. 2017;40:S1–S135.
   Google Scholar
• Bailey TS, Grunberger G, Bode BW, et al. American association of clinical endocrinologists and American college of endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22:231–261.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Global IDF/ISPAD guideline for diabetes in childhood and adolescence. Brussels, Belgium: International Society for Pediatric and Adolescent Diabetes; 2011.
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Hahamian J. Blood glucose test strip utilization within medicare. J Diabetes Sci Technol. 2014;8:429–430.
   PubMedGoogle Scholar
• Mian Z, Hermayer KL, Jenkins A. Continuous glucose monitoring: review of an innovation in diabetes management. Am J Med Sci. 2019;358: 332–339. Epub 2019/ 08/14.
   PubMed Web of Science ®Google Scholar
• Gomez AM, Henao Carrillo DC, Munoz Velandia OM. Devices for continuous monitoring of glucose: update in technology. Med Devices (Auckl). 2017;10: 215–224. Epub 2017/ 10/06.
   PubMedGoogle Scholar
• Abbott Diabetes Care, Inc. Summary of safety and effectiveness data (SSED) of the freestyle libre 14 day flash glucose monitoring system. PMA Number P160030/S017. U.S. Food and Drug Administration Website; 2018 [ Date of FDA Notice of Approval 2018 Jul 23; cited 2019 Nov 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030S017B.pdf
   Google Scholar
• Abbott Diabetes Care Inc. FreeStyle libre 14 day flash glucose monitoring system [user manual]. U.S. Food and Drug Administration website; 2018 [cited 2019 Nov 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030C.pdf.
   Google Scholar
• Dexcom, Inc. Evaluation of automatic class III designation for dexcom G6 continuous glucose monitoring system decision summary. DEN170088. U.S Food and Drug Administration Website; 2018 [cited 2019 Nov 25]. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170088.pdf.
   Google Scholar
• Medtronic MiniMed, Inc. Summary of safety and effectiveness data (SSED) of the guardian connect system. PMA number P160007. U.S. Food and Drug Administration Website; 2018 [ Date of FDA Notice of Approval: 2018 Mar 8; cited 2019 Nov 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160007b.pdf
   Google Scholar
• Medtronic MiniMed, Inc. Guardian connect system [user guide]. U.S. Food and Drug Administration Website; 2018 [ Published 2018; cited 2019 Nov 25]. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160007c.pdf.
   Google Scholar
• Senseonics, Inc. Summary of safety and effectiveness data (SSED) of the eversense continuous glucose monitoring system. PMA Number P160048. U.S. Food and Drug Administration Website; 2018 [ Date of FDA Notice of Approval: 2018 Jun 21; cited 2019 Nov 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048B.pdf.
   Google Scholar
• Senseonics, Inc. Eversense user guide. A guide for using the eversense continuous glucose monitoring system [user guide]. U.S. Food and Drug Administration Website; 2018 [ Revised 2019 Jul 13; cited 2019 Nov 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048c.pdf
   Google Scholar
• Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21:66–72.
   PubMed Web of Science ®Google Scholar
• Ahmed Mohamed I, Fisher A, Cooper P, et al. Use of continuous glucose monitoring in people with type 1 diabetes: perspectives of two people with diabetes and physician perspective. Diabetes Ther. 2019;10:333–340. Epub 2019/ 02/10.
   PubMed Web of Science ®Google Scholar
• Sørgård B, Iversen MM, Mårtensson J. Continuous glucose monitoring in adults with type 1 diabetes: A balance between benefits and barriers: A critical incident study. J Clin Nurs. 2019;28:3318–3329.
   PubMed Web of Science ®Google Scholar
• Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–1476. Epub 2008/ 09/10.
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371–378. Epub 2017/ 01/25.
   PubMed Web of Science ®Google Scholar
• Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379–387. Epub 2017/ 01/25.
   PubMed Web of Science ®Google Scholar
• van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4:893–902. Epub 2016/ 10/30.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Peters AL, Hessler D. The impact of real-time continuous glucose monitoring in patients 65 years and older. J Diabetes Sci Technol. 2016;10: 892–897. Epub 2016/ 03/30.
   PubMedGoogle Scholar
• Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367–1377. Epub 2018/ 02/21.
   PubMed Web of Science ®Google Scholar
• Parkin CG, Graham C, Smolskis J. Continuous glucose monitoring use in type 1 diabetes: longitudinal analysis demonstrates meaningful improvements in HbA1c and reductions in health care utilization. J Diabetes Sci Technol. 2017;11: 522–528. Epub 2017/ 07/27.
   PubMedGoogle Scholar
• Olafsdottir AF, Polonsky W, Bolinder J, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther. 2018;20:274–284. Epub 2018/ 04/03.
   PubMed Web of Science ®Google Scholar
• Abdulrahman A, Manhas J, Linane H, et al. Use of continuous glucose monitoring for sport in type 1 diabetes. BMJ Open Sport Exerc Med. 2018;4:e000432. Epub 2019/ 02/19.
   PubMedGoogle Scholar
• Desjardins K, Brazeau AS, Strychar I, et al. Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes? Diabetes Obesity Metab. 2014;16:577–587.
   PubMed Web of Science ®Google Scholar
• Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5:377–390.
   PubMed Web of Science ®Google Scholar
• Brazeau AS, Rabasa-Lhoret R, Strychar I, et al. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008;31:2108–2109. Epub 2008/ 08/12.
   PubMed Web of Science ®Google Scholar
• Chimen M, Kennedy A, Nirantharakumar K, et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55:542–551. Epub 2011/ 12/23.
   PubMed Web of Science ®Google Scholar
• Tagougui S, Taleb N, Rabasa-Lhoret R. The benefits and limits of technological advances in glucose management around physical activity in patients type 1 diabetes. Front Endocrinol (Lausanne). 2018;9: 818. Epub 2019/ 02/05.
   PubMed Web of Science ®Google Scholar
• Zaharieva DP, Turksoy K, McGaugh SM, et al. Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes. Diabetes Technol Ther. 2019;21:313–321. Epub 2019/ 05/07.
   PubMed Web of Science ®Google Scholar
• Biagi L, Bertachi A, Quiros C, et al. Accuracy of continuous glucose monitoring before, during, and after aerobic and anaerobic exercise in patients with type 1 diabetes mellitus. Biosensors (Basel) 2018;8:1–8. Epub 2018/ 03/10.
   Google Scholar
• Dyck RA, Kleinman NJ, Funk DR, et al. We can work (It) out together: type 1 diabetes boot camp for adult patients and providers improves exercise self-efficacy. Can J Diabetes. 2018;42:619–625.
   PubMed Web of Science ®Google Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–1640.
   PubMed Web of Science ®Google Scholar
• Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593–1603.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40:736–741. Epub 2017/ 04/09.
   PubMed Web of Science ®Google Scholar
• Burckhardt M-A, Abraham MB, Mountain J, et al. Improvement in psychosocial outcomes in children with type 1 diabetes and their parents following subsidy for continuous glucose monitoring. Diabetes Technol Ther. 2019;1–6.
   Google Scholar
• Hilliard ME, Levy W, Anderson BJ, et al. Benefits and barriers of continuous glucose monitoring in young children with type 1 diabetes. Diabetes Technol Ther. 2019;21:493–498. Epub 2019/ 07/10.
   PubMedGoogle Scholar
• Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study. J Clin Endocrinol Metab. 2018;103:1224–1232. Epub 2018/ 01/18.
   PubMed Web of Science ®Google Scholar
• Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390:2347–2359. Epub 2017/ 09/20.
   PubMed Web of Science ®Google Scholar
• Murphy HR, Feig DS, Sanchez JJ, et al. Modelling potential cost savings from use of real-time continuous glucose monitoring in pregnant women with Type 1 diabetes. Diabet Med. 2019;36:1652–1658. Epub 2019/ 06/05.
   PubMed Web of Science ®Google Scholar
• Messer LH, Johnson R, Driscoll KA, et al. Best friend or spy: a qualitative meta-synthesis on the impact of continuous glucose monitoring on life with Type 1 diabetes. Diabet Med. 2018;35:409–418. Epub 2017/ 12/17.
   PubMed Web of Science ®Google Scholar
• Christensen MO, Berg AK, Rytter K, et al. Skin problems due to treatment with technology are associated with increased disease burden among adults with type 1 diabetes. Diabetes Technol Ther. 2019;21:215–221. Epub 2019/ 04/04.
   PubMed Web of Science ®Google Scholar
• Berg AK, Norgaard K, Thyssen JP, et al. Skin problems associated with insulin pumps and sensors in adults with type 1 diabetes: a cross-sectional study. Diabetes Technol Ther. 2018;20:475–482. Epub 2018/ 06/13.
   PubMed Web of Science ®Google Scholar
• Englert K, Ruedy K, Coffey J, et al. Skin and adhesive issues with continuous glucose monitors: a sticky situation. J Diabetes Sci Technol. 2014;8:745–751. Epub 2014/ 05/31.
   PubMedGoogle Scholar
• Shivers JP, Mackowiak L, Anhalt H, et al. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol. 2013;7:789–794. Epub 2013/ 06/14.
   PubMedGoogle Scholar
• Freckmann G, Link M, Kamecke U, et al. Performance and usability of three systems for continuous glucose monitoring in direct comparison. J Diabetes Sci Technol. 2019;13:890–898. Epub 2019/ 02/08.
   PubMedGoogle Scholar
• Welsh JB, Gao P, Derdzinski M, et al. Accuracy, utilization, and effectiveness comparisons of different continuous glucose monitoring systems. Diabetes Technol Ther. 2019;21:128–132. Epub 2019/ 01/27.
   PubMed Web of Science ®Google Scholar
• Freckmann G, Link M, Pleus S, et al. Measurement performance of two continuous tissue glucose monitoring systems intended for replacement of blood glucose monitoring. Diabetes Technol Ther. 2018;20:541–549. Epub 2018/ 08/02.
   PubMed Web of Science ®Google Scholar
• Lorenz C, Sandoval W, Mortellaro M. Interference assessment of various endogenous and exogenous substances on the performance of the eversense long-term implantable continuous glucose monitoring system. Diabetes Technol Ther. 2018;20: 344–352. Epub 2018/ 03/31.
   PubMed Web of Science ®Google Scholar
• Basu A, Slama MQ, Nicholson WT, et al. Continuous glucose monitor interference with commonly prescribed medications: a pilot study. J Diabetes Sci Technol. 2017;11:936–941. Epub 2017/ 03/24.
   PubMedGoogle Scholar
• Basu A, Veettil S, Dyer R, et al. Direct evidence of acetaminophen interference with subcutaneous glucose sensing in humans: a pilot study. Diabetes Technol Ther. 2016;18(Suppl 2):S243–7. Epub 2016/ 01/20.
   PubMedGoogle Scholar
• Maahs DM, DeSalvo D, Pyle L, et al. Effect of acetaminophen on CGM glucose in an outpatient setting. Diabetes Care. 2015;38:e158–9. Epub 2015/ 08/14.
   PubMed Web of Science ®Google Scholar
• Schiavon M, Acciaroli G, Vettoretti M, et al. A model of acetaminophen pharmacokinetics and its effect on continuous glucose monitoring sensor measurements. Conf Proc IEEE Eng Med Biol Soc. 2018;2018:159–162. Epub 2018/ 11/18.
   PubMedGoogle Scholar
• Mensh BD, Wisniewski NA, Neil BM, et al. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol. 2013;7:863–870. Epub 2013/ 08/06.
   PubMedGoogle Scholar
• James S, Perry L, Gallagher R, et al. Diabetes educators: perceived experiences, supports and barriers to use of common diabetes-related technologies. J Diabetes Sci Technol. 2016;10:1115–1121. Epub 2016/ 07/16.
   PubMedGoogle Scholar
• Tanenbaum ML, Adams RN, Lanning MS, et al. Using cluster analysis to understand clinician readiness to promote continuous glucose monitoring adoption. J Diabetes Sci Technol. 2018;12:1108–1115. Epub 2018/ 07/12.
   PubMedGoogle Scholar
• Hirsch IB, Welsh JB, Calhoun P, et al. Associations between HbA 1c and continuous glucose monitoring‐derived glycaemic variables. Diabetic Med. 2019;36:1637–1642.
   PubMed Web of Science ®Google Scholar
• Runge AS, Kennedy L, Brown AS, et al. Does time-in-range matter? perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes. Clin Diabetes. 2018;36:112–119. Epub 2018/ 04/25.
   PubMedGoogle Scholar
• Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. Diabetologia. 2019;62: 1123–1128. Epub 2019/ 06/05.
   PubMed Web of Science ®Google Scholar
• Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400–405. Epub 2018/ 10/26.
   PubMed Web of Science ®Google Scholar
• Comstock J Novo Nordisk to launch two connected insulin pens, taps Flex to manage data. MobiHealthNews [Internet]. 2018 September 1, 2019. Available from: https://www.mobihealthnews.com/content/novo-nordisk-launch-two-connected-insulin-pens-taps-flex-manage-data.
   Google Scholar
• Comstock J Novo Nordisk’s new insulin pens will integrate with abbott’s freestyle libre system. MobiHealthNews [Internet]. 2019 [cited 2019 Sept 1. Available from: https://www.mobihealthnews.com/content/novo-nordisks-new-insulin-pens-will-integrate-abbotts-freestyle-libre-system.
   Google Scholar
• Hoskins M. Eight Hours Inside Bigfoot’s Diabetes Lair. Healthline Internet]. 2019 cited 2019 Sept 05. Available from. []. : https://www.healthline.com/diabetesmine/bigfoot-biomedical-diabetes-tech-visit#6
   Google Scholar
• Pettus J, Edelman SV. Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes. J Diabetes Sci Technol. 2017;11: 138–147. Epub 2016/ 08/18.
   PubMedGoogle Scholar
• Aleppo G, Laffel LM, Ahmann AJ, et al. A practical approach to using trend arrows on the dexcom G5 CGM system for the management of adults with diabetes. J Endocr Soc. 2017;1:1445–1460. Epub 2018/ 01/19.
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Kerr D. A simplified approach using rate of change arrows to adjust insulin with real-time continuous glucose monitoring. J Diabetes Sci Technol. 2017;11: 1063–1069. Epub 2017/ 09/09.
   PubMedGoogle Scholar
• Freckmann G, Link M, Westhoff A, et al. Prediction quality of glucose trend indicators in two continuous tissue glucose monitoring systems. Diabetes Technol Ther. 2018;20:550–556. Epub 2018/ 08/02.
   PubMedGoogle Scholar
• Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7:562–578. Epub 2013/04/10.
   PubMedGoogle Scholar